alexa Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial.
Healthcare

Healthcare

Journal of Community Medicine & Health Education

Author(s): Porto AM, Coutinho IC, Correia JB, Amorim MM

Abstract Share this page

Abstract OBJECTIVES: To determine the effectiveness of corticosteroids in reducing respiratory disorders in infants born at 34-36 weeks' gestation. Design Randomised triple blind clinical trial. Setting A large tertiary teaching hospital in northeast of Brazil. Participants Women at 34-36 weeks of pregnancy at risk of imminent premature delivery. Interventions Betamethasone 12 mg or placebo intramuscularly for two consecutive days. Main outcomes measures Primary outcome was the incidence of respiratory disorders (respiratory distress syndrome and transient tachypnoea of the newborn). Secondary outcomes included the need for ventilatory support, neonatal morbidity, and duration of stay in hospital. RESULTS: 320 women were randomised, 163 of whom were assigned to the treatment group and 157 to the controls. Final analysis included 143 and 130 infants, respectively. The rate of respiratory distress syndrome was low (two (1.4\%) in the corticosteroid group; one (0.8\%) in the placebo group; P = 0.54), while the rate of transient tachypnoea was high in both groups (34 (24\%) v 29 (22\%); P = 0.77). There was no reduction in the risk of respiratory morbidity with corticosteroid use even after adjustment for subgroups of gestational age (34-34(+6) weeks, 35-35(+6) weeks, and ≥ 36 weeks). The adjusted risk of respiratory morbidity was 1.12 (95\% confidence interval 0.74 to 1.70). The need for ventilatory support was around 20\% in both groups. There was no difference in neonatal morbidity (88 (62\%) v 93 (72\%); P = 0.08) or in the duration of stay in hospital between the two groups (5.12 v 5.22 days; P = 0.87). Phototherapy for jaundice was required less often in babies whose mothers received corticosteroids (risk ratio 0.63, 0.44 to 0.91). CONCLUSIONS: Antenatal treatment with corticosteroids at 34-36 weeks of pregnancy does not reduce the incidence of respiratory disorders in newborn infants. Trial registration Clinical Trials NCT00675246.
This article was published in BMJ and referenced in Journal of Community Medicine & Health Education

Relevant Expert PPTs

Recommended Conferences

  • 23rd World Nursing and Healthcare Conference
    Jul 10-12, 2017, Golden Tulip Berlin - Hotel Hamburg, Berlin, Germany
  • 10th World Congress on Healthcare & Technologies
    Jul 17-18, 2017, Lisbon, Portugal
  • 30th Nursing and Healthcare Congress
    Aug 21-23, 2017, Toronto, Canada

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords